Northvale, NJ, Oct. 06, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — ADM Tronics Unlimited, Inc. (OTCQB: ADMT) has been advised that Origin, Inc. filed an Investigational Device Exemption (“IDE”) application with the FDA to conduct clinical studies to treat patients diagnosed with COVID-19 with its plasma-generated nitric oxide (“NO”) technology. ADMT has been developing and has manufactured for Origin, Inc. the IonoJet™, which allows for targeted delivery of NO generated by a thermal plasma, produced from room air at the point of therapy.
Michael Preston, Chairman and President of Origin, Inc., stated, “Like other nitric oxide companies, we have recognized the potential ability of NO to stop the replication of corona viruses. We believe there may be limitations with other approaches, and we have worked to address these in a novel system that is designed to allow NO to be administered effectively. ADMT has been key to our development and